Vanda Pharmaceuticals (VNDA) Competitors

$5.95 -0.05 (-0.83%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$5.97 +0.02 (+0.40%)

As of 06/23/2026 07:24 PM Eastern

VNDA vs. MNKD, ZBIO, OPK, LXRX, and GERN

Should you buy Vanda Pharmaceuticals stock or one of its competitors? MarketBeat compares Vanda Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vanda Pharmaceuticals include MannKind (MNKD), Zenas BioPharma (ZBIO), OPKO Health (OPK), Lexicon Pharmaceuticals (LXRX), and Geron (GERN). These companies are all part of the "biotechnology" industry.

How does Vanda Pharmaceuticals compare to MannKind?

MannKind (NASDAQ:MNKD) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

MannKind has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

MannKind presently has a consensus target price of $8.97, indicating a potential upside of 128.21%. Vanda Pharmaceuticals has a consensus target price of $14.30, indicating a potential upside of 140.34%. Given Vanda Pharmaceuticals' higher possible upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

MannKind has a net margin of -6.63% compared to Vanda Pharmaceuticals' net margin of -109.99%. MannKind's return on equity of -11.21% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

49.6% of MannKind shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MannKind has higher revenue and earnings than Vanda Pharmaceuticals. MannKind is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.48	$5.86M	-$0.07	N/A
Vanda Pharmaceuticals	$216.10M	1.66	-$220.47M	-$4.05	N/A

In the previous week, MannKind had 3 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 3 mentions for MannKind and 0 mentions for Vanda Pharmaceuticals. MannKind's average media sentiment score of 1.17 beat Vanda Pharmaceuticals' score of 0.00 indicating that MannKind is being referred to more favorably in the media.

Company	Overall Sentiment
MannKind	Positive
Vanda Pharmaceuticals	Neutral

Summary

MannKind beats Vanda Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Zenas BioPharma?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Zenas BioPharma has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -109.99%. Vanda Pharmaceuticals' return on equity of -32.26% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
Zenas BioPharma	N/A	-99.99%	-58.06%

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vanda Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.66	-$220.47M	-$4.05	N/A
Zenas BioPharma	$10M	127.52	-$377.74M	-$8.47	N/A

In the previous week, Zenas BioPharma had 4 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 4 mentions for Zenas BioPharma and 0 mentions for Vanda Pharmaceuticals. Zenas BioPharma's average media sentiment score of 0.90 beat Vanda Pharmaceuticals' score of 0.00 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Vanda Pharmaceuticals	Neutral
Zenas BioPharma	Positive

Vanda Pharmaceuticals presently has a consensus price target of $14.30, indicating a potential upside of 140.34%. Zenas BioPharma has a consensus price target of $44.29, indicating a potential upside of 119.24%. Given Vanda Pharmaceuticals' higher probable upside, research analysts plainly believe Vanda Pharmaceuticals is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Vanda Pharmaceuticals has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, suggesting that its share price is 171% less volatile than the broader market.

Summary

Vanda Pharmaceuticals beats Zenas BioPharma on 9 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

OPKO Health currently has a consensus price target of $1.55, suggesting a potential upside of 6.16%. Vanda Pharmaceuticals has a consensus price target of $14.30, suggesting a potential upside of 140.34%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, OPKO Health had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 1 mentions for OPKO Health and 0 mentions for Vanda Pharmaceuticals. OPKO Health's average media sentiment score of 0.74 beat Vanda Pharmaceuticals' score of 0.00 indicating that OPKO Health is being referred to more favorably in the media.

Company	Overall Sentiment
OPKO Health	Positive
Vanda Pharmaceuticals	Neutral

64.6% of OPKO Health shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 44.7% of OPKO Health shares are held by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

OPKO Health has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Vanda Pharmaceuticals has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.82	-$225.68M	-$0.27	N/A
Vanda Pharmaceuticals	$216.10M	1.66	-$220.47M	-$4.05	N/A

OPKO Health has a net margin of -36.63% compared to Vanda Pharmaceuticals' net margin of -109.99%. OPKO Health's return on equity of -16.78% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

Summary

OPKO Health beats Vanda Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vanda Pharmaceuticals currently has a consensus target price of $14.30, suggesting a potential upside of 140.34%. Lexicon Pharmaceuticals has a consensus target price of $4.55, suggesting a potential upside of 110.65%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Vanda Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Lexicon Pharmaceuticals has lower revenue, but higher earnings than Vanda Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.66	-$220.47M	-$4.05	N/A
Lexicon Pharmaceuticals	$49.80M	19.27	-$50.34M	-$0.07	N/A

Lexicon Pharmaceuticals has a net margin of -37.46% compared to Vanda Pharmaceuticals' net margin of -109.99%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Vanda Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

In the previous week, Lexicon Pharmaceuticals' average media sentiment score of 1.00 beat Vanda Pharmaceuticals' score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Vanda Pharmaceuticals	Neutral
Lexicon Pharmaceuticals	Positive

Summary

Lexicon Pharmaceuticals beats Vanda Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Geron?

Geron (NASDAQ:GERN) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Geron presently has a consensus price target of $2.50, suggesting a potential upside of 85.19%. Vanda Pharmaceuticals has a consensus price target of $14.30, suggesting a potential upside of 140.34%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Geron had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 1 mentions for Geron and 0 mentions for Vanda Pharmaceuticals. Geron's average media sentiment score of 0.00 equaled Vanda Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Geron	Neutral
Vanda Pharmaceuticals	Neutral

Geron has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

73.7% of Geron shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Geron has higher earnings, but lower revenue than Vanda Pharmaceuticals. Geron is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.71	-$83.50M	-$0.11	N/A
Vanda Pharmaceuticals	$216.10M	1.66	-$220.47M	-$4.05	N/A

Geron has a net margin of -35.48% compared to Vanda Pharmaceuticals' net margin of -109.99%. Geron's return on equity of -23.31% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

Summary

Vanda Pharmaceuticals beats Geron on 8 of the 15 factors compared between the two stocks.

Get Vanda Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VNDA vs. The Competition

Export

Metric	Vanda Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$360.81M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-1.47	19.75	24.92	23.98
Price / Sales	1.66	330.90	528.23	109.07
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.07	8.29	10.79	6.50
Net Income	-$220.47M	$23.85M	$3.56B	$336.88M
7 Day Performance	-0.17%	2.87%	1.00%	-0.14%
1 Month Performance	-3.88%	2.19%	0.42%	0.77%
1 Year Performance	32.22%	55.48%	29.70%	28.49%

Vanda Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VNDA Vanda Pharmaceuticals	1.6917 of 5 stars	$5.95 -0.8%	$14.30 +140.3%	+33.1%	$360.81M	$216.10M	N/A	290
MNKD MannKind	3.0881 of 5 stars	$4.00 +9.3%	$8.97 +124.2%	+3.4%	$1.24B	$348.97M	N/A	400
ZBIO Zenas BioPharma	3.5844 of 5 stars	$18.71 -5.5%	$44.29 +136.7%	+113.3%	$1.18B	$10M	N/A	N/A	Gap Up
OPK OPKO Health	1.1249 of 5 stars	$1.40 -1.4%	$1.55 +10.7%	+15.0%	$1.06B	$606.90M	N/A	1,373
LXRX Lexicon Pharmaceuticals	1.717 of 5 stars	$1.96 +2.1%	$4.55 +132.1%	+194.2%	$870.62M	$69.64M	N/A	140	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VNDA) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. MNKD, ZBIO, OPK, LXRX, and GERN

How does Vanda Pharmaceuticals compare to MannKind?

Summary

How does Vanda Pharmaceuticals compare to Zenas BioPharma?

Summary

How does Vanda Pharmaceuticals compare to OPKO Health?

Summary

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Summary

How does Vanda Pharmaceuticals compare to Geron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. MNKD, ZBIO, OPK, LXRX, and GERN

How does Vanda Pharmaceuticals compare to MannKind?

Which has more volatility & risk, MNKD or VNDA?

Do analysts rate MNKD or VNDA?

Is MNKD or VNDA more profitable?

Do institutionals & insiders believe in MNKD or VNDA?

Which has stronger valuation & earnings, MNKD or VNDA?

Does the media prefer MNKD or VNDA?

Summary

How does Vanda Pharmaceuticals compare to Zenas BioPharma?

Is VNDA or ZBIO more profitable?

Do institutionals and insiders believe in VNDA or ZBIO?

Which has higher valuation & earnings, VNDA or ZBIO?

Does the media favor VNDA or ZBIO?

Do analysts prefer VNDA or ZBIO?

Which has more risk & volatility, VNDA or ZBIO?

Summary

How does Vanda Pharmaceuticals compare to OPKO Health?

Do analysts recommend OPK or VNDA?

Does the media refer more to OPK or VNDA?

Do institutionals & insiders hold more shares of OPK or VNDA?

Which has more risk & volatility, OPK or VNDA?

Which has better valuation and earnings, OPK or VNDA?

Is OPK or VNDA more profitable?

Summary

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Do institutionals and insiders have more ownership in VNDA or LXRX?

Do analysts recommend VNDA or LXRX?

Which has stronger valuation and earnings, VNDA or LXRX?

Is VNDA or LXRX more profitable?

Which has more volatility & risk, VNDA or LXRX?

Does the media favor VNDA or LXRX?

Summary

How does Vanda Pharmaceuticals compare to Geron?

Do analysts prefer GERN or VNDA?

Does the media refer more to GERN or VNDA?

Which has more volatility & risk, GERN or VNDA?

Do insiders and institutionals hold more shares of GERN or VNDA?

Which has higher valuation and earnings, GERN or VNDA?

Is GERN or VNDA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools